Fermi Inc. has dismissed former CEO Toby Neugebauer's efforts to call special shareholder meetings as invalid and self-serving, urging shareholders not to support his proposals. Neugebauer, removed for cause after poor stock performance and policy violations, sought to expand the board with his nominees and push for a quick sale of the company. Fermi emphasizes its strategic plan under new leadership, supported by investors, to build on Project Matador and rejects an immediate sale as premature. Shareholders are encouraged to back the current board and management for Fermi's future success.
A new report reveals more than 180 companies are actively developing over 200 PD-1 and PD-L1 inhibitors, a class of immunotherapies that boost the immune system to fight cancer. These drugs target various cancers including lung, bladder, liver, and e...
Eversource has been recognized on TIME's list of America's Best Companies for 2026, highlighting its strong commitment to employee satisfaction, operational excellence, and sustainability. The ranking is based on surveys of over 217,000 employees and...
The head and neck squamous cell carcinoma (HNSCC) market is projected to grow at a compound annual growth rate (CAGR) of 10.5% from 2026 to 2036, fueled by rising cancer incidence and the introduction of novel immunotherapies and targeted treatments....
Poolside has released Laguna S 2.1, a 118-billion-parameter open-weight AI model designed for agentic coding that matches or outperforms much larger models. It is compact enough to run on a single NVIDIA DGX Spark desktop and is available under an op...
Pomerantz LLP is investigating Omeros Corporation for potential securities fraud following a significant stock price drop. The decline occurred after the European Medicines Agency's Committee for Medicinal Products for Human Use issued a negative opi...
